DataMeds AI, Inc. earnings releases MEDS

Annual Quarterly

DataMeds AI, Inc. last reported quarterly results on Aug 18, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): revenue of $1.8 million (-77.2% year over year) and diluted EPS of -$7.13. It usually reports 49–53 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 19, 2026.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 49–53 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Aug 18, 2026
49 days after quarter end
Q2 FY2026
ended Jun 30, 2026
2
-77.2%
-18
-175.2%
-7.13
-32.0%
May 19, 2026
49 days after quarter end
Q1 FY2026
ended Mar 31, 2026
2
-85.6%
-8
+76.1%
-0.07
+88.7%
Nov 20, 2025
51 days after quarter end
Q3 FY2025
ended Sep 30, 2025
3
-34
-0.46
Aug 22, 2025
53 days after quarter end
Q2 FY2025
ended Jun 30, 2025
8
-7
-5.40

Company profile

Industry
Wholesale-Drugs, Proprietaries & Druggists' Sundries (SIC 5122)
Listed as
MEDS (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Tampa, FL
SEC filer status
, Emerging growth company
SEC CIK
2030763
Former names
Wellgistics Health, Inc. (until Jul 21, 2026); Danam Health, Inc (until Sep 27, 2024)

Other Wholesale-Drugs, Proprietaries & Druggists' Sundries companies

All 11 Wholesale-Drugs, Proprietaries & Druggists' Sundries companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.